

Supplementary Data

The TP53 web site: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

Bernard Leroy¹, Jean Louis Fournier¹, Chikashi Ishioka², Paola Monti³, Alberto Inga⁴ Gilberto Fronza³ and Thierry Soussi^{1,5,*}

¹Université Pierre et Marie Curie-Paris6 75005 Paris, France

²Department of Clinical Oncology; Institute of Development, Aging and Cancer; Tohoku University; Sendai, Japan;

³Molecular Mutagenesis and DNA Repair Unit, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy;

⁴Laboratory of Transcriptional Networks, Centre for Integrative Biology, University of Trento, Trento, Italy;

⁵Karolinska Institute Dept. of Oncology-Pathology Cancer Center Karolinska (CCK), SE-171 76 Stockholm, Sweden

Table of Content

Supplementary figure 1: Timeline of the evolution of the UMD TP53 database and description of TP53 mutations.


Supplementary figure 2: A: Frequency of TP53 mutations in each exon of the TP53 gene according to the sequencing strategy, NGS (Blue) or conventional sequencing (Red). Only studies that targeted the entire TP53 gene were included in the analysis. B: frequency of missense and frameshift mutations (blue and red, respectively) in each exon of the TP53 gene. Exons 2, 3 and 11 have been omitted due to the very low frequency of mutations in these exons.

Supplementary table 1: Relationship Between TP53 gene mutations and exposure to carcinogens (adapted with permission from) (1).



Supplementary table 2: Incidence of the five most frequent TP53 mutations in various types of cancer. Red: mutations specific to a specific type of cancer.

Supplementary table 3: Classification of the 26 characteristics used in MUTLOAD.

1. Soussi,T. (2011) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. *Adv Cancer Res* 110, 107-139.



Supplemental Figure S1



Supplemental Figure S2

Supplementary table 1: Relationship between TP53 gene mutations and exposure to carcinogens.

| Type of cancer | Characteristics of TP53 mutations ¹ | Genotoxic agent incriminated | Comments | References |
|-----------------------------------|---|--|---|---|
| Urothelial malignancy | High frequency of A:T -> T:A transversions | Aristolochic acids | Exposure of cells to Aristolochic acid leads to similar mutational events | {Grollman et al., 2007, #102859; Nedelko et al., 2009, #83731} |
| Hepatocellular carcinoma | Specific G->T transversions in codon 249 | Aflatoxin B1 | Aflatoxin B1 binds specifically to codon 249 | {Puisieux et al., 1991, #42441 ;Staib et al., 2003, #79650} |
| Hepatic angiosarcoma | High frequency of A:T -> T:A transversions | Vinyl chloride | | {Hollstein et al., 1994, #26675} |
| Lung cancer | High frequency of G->T transversions ² Hot spot on codons 157 and 158 | Benzo(a)pyrene (cigarette smoke) | Benzo(a)pyrene has a particular affinity for codons 157 and 158 | {Denissenko et al., 1996, #34661 ;Toyooka et al., 2003, #58714} |
| Skin cancer (BCC and SCC) | Very high frequency of mutations on pyrimidine dimers High frequency of tandem mutations | Ultraviolet radiation | Photo-induced mutations | {Brash et al., 1991, #1302 ;Tornaletti et al., 1993, #22774} |
| Wilson's disease, hemochromatosis | Specific G->T transversions in codon 249 | In these diseases related to iron or copper overload, overproduction of free radicals leads to high oxidative stress | Exposure of cells to a carcinogen derived from lipid peroxidation leads to alterations on codon 249 of the TP53 gene. | {Hussain et al., 2000, #45371 ;Marrogi et al., 2001, #78923} |

¹ compared to TP53 mutations observed in the absence of exposure to the agent incriminated.

² this high frequency of transversion is also observed in cancers of the esophagus and head and neck cancers associated with drinking and smoking.

Only the most striking observations are summarized in this table. For more details, the reader can refer to the review by Hofseth et al. {Hofseth et al., 2004, #86888}
Adapted from {Soussi, 2011, #11392} with permission.

| | 1 | 2 | 3 | 4 | 5 |
|-----------------------|---------------------|--------------------|-------------|--------------------|-------------|
| Colorectal ca. | R175H (9.7) | R248Q (5.9) | R273H (5.4) | R282W (5.1) | R248W (4.9) |
| Breast ca. | R175H (4.0) | R248Q (3.5) | R273H (3) | R248W (2.4) | Y220C (1.7) |
| Lung (NSCLC) | R248L (2.3) | R158L (2.1) | R273H (1.9) | V157F (1.9) | R249S (1.8) |
| Bladder ca. | E285K (4.7) | R280T (3.2) | R248Q (3.1) | R175H (2.3) | R280K (2) |
| HNSCC | R248Q (2.9) | R175H (2.8) | R273H (2.3) | R282W (2) | Y220C (1.9) |
| HCC | R249S (33.5) | V157F (2.1) | R273C (1.7) | Y220C (1.2) | R248Q (0.9) |
| Ovarian ca. | R175H (4.6) | R273H (4.1) | Y220C (2.8) | R248Q (2.6) | R273C (2.6) |
| Gastric ca. | R175H (6.9) | R282W (4.9) | R273H (3.5) | R248Q (3.5) | G245S (3.3) |
| Prostate ca. | R273C (4) | R175H (2.5) | R273H (2.2) | I251S (1.9) | R248W (1.5) |

Supplemental Table 2

| Transcription | Structure | Cell Biology | Gain of Function |
|--|--------------------|--|------------------------------------|
| Transactivation | Binding to hsp 70 | Growth arrest | Mutant-specific transactivation |
| Dominant negative activity for transactivation | Binding to PAb1620 | Apoptosis | Interference with p73/p63 activity |
| In vitro DNA binding | Binding to PAb 240 | Dominant negative activity for growth arrest | Mutant-specific DNA binding |
| In vivo DNA binding | Oligomerization | Dominant negative activity for apoptosis | Mutant-specific protein binding |
| | Folding | Localization | Mutant-specific activity |
| | Oligomerization | Mitochondrial apoptosis | Mutant p53 Ko phenotype |
| | Protein binding | Autophagy | |
| | Modification | | |
| | Exonuclease | | |

Supplemental Table 3